474017-65-7

Basic information

• Product Name: 2-(4-ethoxybenzyl)-N,N-diethyl-3-isopentyl-3H-imidazo[4,5-b]pyridine-6-carboxamide
• CAS NO: 474017-65-7
• Molecular Weight: 422.571
• Mol File: 474017-65-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(4-ethoxybenzyl)-N,N-diethyl-3-isopentyl-3H-imidazo[4,5-b]pyridine-6-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-ethoxybenzyl)-N,N-diethyl-3-isopentyl-3H-imidazo[4,5-b]pyridine-6-carboxamide(474017-65-7)
• EPA Substance Registry System: 2-(4-ethoxybenzyl)-N,N-diethyl-3-isopentyl-3H-imidazo[4,5-b]pyridine-6-carboxamide(474017-65-7)

Safety Data

• Hazardous Substances Data: 474017-65-7(Hazardous Substances Data)

Upstream product

• 7477-10-3 6-chloro-5-nitronicotinic acid 

Relevant articles and documents

Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders

A pharmacophore model for butyrylcholinesterase (BChE) inhibitors was applied to a human cannabinoid subtype 2 receptor (hCB2R) agonist and verified it as a first-generation lead for respective dual-acting compounds. The design, synthesis, and pharmacological evaluation of various derivatives led to the identification of aminobenzimidazoles as second-generation leads with micro- or sub-micromolar activities at both targets and excellent selectivity over hCB1and AChE, respectively. Computational studies of the first- and second-generation lead structures by applying molecular dynamics (MD) on the active hCB2R model, along with docking and MD on hBChE, has enabled an explanation of their binding profiles at the protein levels and opened the way for further optimization. Dual-acting compounds with “balanced” affinities and excellent selectivities could be obtained that represent leads for treatment of both cognitive and pathophysiological impairment occurring in neurodegenerative disorders.